Orchid Pharma Ltd, a wholly owned subsidiary in India, namely Orchid Bio-Pharma Limited had made an application with the Competent Authority under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) / Active Pharmaceutical Ingredients (APIs) in India.

The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA" with a committed capacity of 1000 Metric Tonne Per Annum. This approval will help the company in backward integration, reduce dependency on sourcing from China and aid in improving margins.